Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity.

Kalinichev M, Girard F, Haddouk H, Rouillier M, Riguet E, Royer-Urios I, Mutel V, Lütjens R, Poli S.

Neuropharmacology. 2017 Mar 1;114:34-47. doi: 10.1016/j.neuropharm.2016.11.016. Epub 2016 Nov 23.

PMID:
27889489
2.

Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile.

Kalinichev M, Donovan-Rodriguez T, Girard F, Riguet E, Rouillier M, Bournique B, Haddouk H, Mutel V, Poli S.

Br J Pharmacol. 2014 Nov;171(21):4941-54. doi: 10.1111/bph.12812. Epub 2014 Sep 5.

3.

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.

Bezard E, Pioli EY, Li Q, Girard F, Mutel V, Keywood C, Tison F, Rascol O, Poli SM.

Mov Disord. 2014 Jul;29(8):1074-9. doi: 10.1002/mds.25920. Epub 2014 May 27.

PMID:
24865335
4.

Inhibition of follicle-stimulating hormone-induced preovulatory follicles in rats treated with a nonsteroidal negative allosteric modulator of follicle-stimulating hormone receptor.

Dias JA, Campo B, Weaver BA, Watts J, Kluetzman K, Thomas RM, Bonnet B, Mutel V, Poli SM.

Biol Reprod. 2014 Jan 30;90(1):19. doi: 10.1095/biolreprod.113.109397. Print 2014 Jan.

5.

ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.

Kalinichev M, Rouillier M, Girard F, Royer-Urios I, Bournique B, Finn T, Charvin D, Campo B, Le Poul E, Mutel V, Poli S, Neale SA, Salt TE, Lütjens R.

J Pharmacol Exp Ther. 2013 Mar;344(3):624-36. doi: 10.1124/jpet.112.200915. Epub 2012 Dec 20. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):328.

PMID:
23257312
6.

Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation.

Schelshorn D, Joly F, Mutel S, Hampe C, Breton B, Mutel V, Lütjens R.

Mol Pharmacol. 2012 Mar;81(3):309-18. doi: 10.1124/mol.111.074757. Epub 2011 Nov 22.

PMID:
22108912
7.

mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents.

Rocher JP, Bonnet B, Boléa C, Lütjens R, Le Poul E, Poli S, Epping-Jordan M, Bessis AS, Ludwig B, Mutel V.

Curr Top Med Chem. 2011;11(6):680-95. Review.

PMID:
21261592
8.

A negative allosteric modulator demonstrates biased antagonism of the follicle stimulating hormone receptor.

Dias JA, Bonnet B, Weaver BA, Watts J, Kluetzman K, Thomas RM, Poli S, Mutel V, Campo B.

Mol Cell Endocrinol. 2011 Feb 20;333(2):143-50. doi: 10.1016/j.mce.2010.12.023. Epub 2010 Dec 22.

9.

Altered distribution of mGlu2 receptors in β-amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice.

Richards G, Messer J, Faull RL, Stadler H, Wichmann J, Huguenin P, Bohrmann B, Mutel V.

Brain Res. 2010 Dec 2;1363:180-90. doi: 10.1016/j.brainres.2010.09.072. Epub 2010 Sep 25.

PMID:
20875805
10.

Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers.

Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1666-9. doi: 10.1016/j.bmcl.2009.01.108. Epub 2009 Feb 6.

PMID:
19233648
11.

Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.

Woltering TJ, Wichmann J, Goetschi E, Adam G, Kew JN, Knoflach F, Ballard TM, Huwyler J, Mutel V, Gatti S.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2725-9. doi: 10.1016/j.bmcl.2008.02.076. Epub 2008 Mar 5.

PMID:
18374569
12.

Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: part 2. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.

Woltering TJ, Adam G, Wichmann J, Goetschi E, Kew JN, Knoflach F, Mutel V, Gatti S.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1091-5. Epub 2007 Dec 8.

PMID:
18096387
13.

Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA.

Woltering TJ, Adam G, Huguenin P, Wichmann J, Kolczewski S, Gatti S, Bourson A, Kew JN, Richards G, Kemp JA, Mutel V, Knoflach F.

ChemMedChem. 2008 Feb;3(2):323-35.

PMID:
18058780
14.

Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: new potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1.

Woltering TJ, Adam G, Alanine A, Wichmann J, Knoflach F, Mutel V, Gatti S.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6811-5. Epub 2007 Oct 17.

PMID:
17964783
15.

The pros of not being competitive.

Mutel V, Bettler B.

Curr Neuropharmacol. 2007 Sep;5(3):148. doi: 10.2174/157015907781695964. No abstract available.

16.

Cellular prion protein signaling in serotonergic neuronal cells.

Mouillet-Richard S, Schneider B, Pradines E, Pietri M, Ermonval M, Grassi J, Richards JG, Mutel V, Launay JM, Kellermann O.

Ann N Y Acad Sci. 2007 Jan;1096:106-19. Review.

PMID:
17405922
17.

Control of bioamine metabolism by 5-HT2B and alpha 1D autoreceptors through reactive oxygen species and tumor necrosis factor-alpha signaling in neuronal cells.

Schneider B, Pietri M, Mouillet-Richard S, Ermonval M, Mutel V, Launay JM, Kellermann O.

Ann N Y Acad Sci. 2006 Dec;1091:123-41.

PMID:
17341609
18.

Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists.

Jaeschke G, Porter R, Büttelmann B, Ceccarelli SM, Guba W, Kuhn B, Kolczewski S, Huwyler J, Mutel V, Peters JU, Ballard T, Prinssen E, Vieira E, Wichmann J, Spooren W.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1307-11. Epub 2006 Dec 15.

PMID:
17196387
19.

9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers.

Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4628-31.

PMID:
16099654
20.

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.

Porter RH, Jaeschke G, Spooren W, Ballard TM, Büttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, Mühlemann A, Gatti S, Mutel V, Malherbe P.

J Pharmacol Exp Ther. 2005 Nov;315(2):711-21. Epub 2005 Jul 22.

PMID:
16040814
21.

Stepwise control of osteogenic differentiation by 5-HT(2B) receptor signaling: nitric oxide production and phospholipase A2 activation.

Locker M, Bitard J, Collet C, Poliard A, Mutel V, Launay JM, Kellermann O.

Cell Signal. 2006 May;18(5):628-39. Epub 2005 Jul 12.

PMID:
16014328
22.

Reactive oxygen species-dependent TNF-alpha converting enzyme activation through stimulation of 5-HT2B and alpha1D autoreceptors in neuronal cells.

Pietri M, Schneider B, Mouillet-Richard S, Ermonval M, Mutel V, Launay JM, Kellermann O.

FASEB J. 2005 Jul;19(9):1078-87.

PMID:
15985531
23.

Opposite effects of Zn on the in vitro binding of [3H]LY354740 to recombinant and native metabotropic glutamate 2 and 3 receptors.

Malherbe P, Richards JG, Broger C, Zenner MT, Messer J, Kratzeisen C, Nakanishi S, Mutel V.

J Neurochem. 2005 Jul;94(1):150-60.

25.

Modulation of serotonergic receptor signaling and cross-talk by prion protein.

Mouillet-Richard S, Pietri M, Schneider B, Vidal C, Mutel V, Launay JM, Kellermann O.

J Biol Chem. 2005 Feb 11;280(6):4592-601. Epub 2004 Dec 8.

26.

Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.

Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G, Woltering T, Nakanishi S, Mutel V.

Neuropharmacology. 2004 Jun;46(7):907-17.

PMID:
15081787
27.

NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells.

Schneider B, Mutel V, Pietri M, Ermonval M, Mouillet-Richard S, Kellermann O.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13326-31. Epub 2003 Nov 3.

28.

Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket.

Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, Paoletti P, Kew JN.

J Pharmacol Exp Ther. 2003 Dec;307(3):897-905. Epub 2003 Oct 8.

PMID:
14534359
29.

1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists.

Alanine A, Bourson A, Büttelmann B, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3155-9.

PMID:
12951084
30.

Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders.

Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R.

Behav Pharmacol. 2003 Jul;14(4):257-77. Review.

PMID:
12838033
31.

4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.

Büttelmann B, Alanine A, Bourson A, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R.

Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.

PMID:
12729659
32.

2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.

Büttelmann B, Alanine A, Bourson A, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R.

Bioorg Med Chem Lett. 2003 Mar 10;13(5):829-32.

PMID:
12617901
33.

Alkyl diphenylacetyl, 9H-xanthene- and 9H-thioxanthene-carbonyl carbamates as positive allosteric modulators of mGlu1 receptors.

Wichmann J, Bleicher K, Vieira E, Woltering T, Knoflach F, Mutel V.

Farmaco. 2002 Dec;57(12):989-92.

PMID:
12564473
34.

Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum.

Malherbe P, Kew JN, Richards JG, Knoflach F, Kratzeisen C, Zenner MT, Faull RL, Kemp JA, Mutel V.

Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):168-78.

PMID:
12531526
35.

Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor.

Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JN, Kratzeisen C, Maerki HP, Adam G, Mutel V.

J Biol Chem. 2003 Mar 7;278(10):8340-7. Epub 2002 Dec 30.

36.
37.

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.

Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA.

J Pharmacol Exp Ther. 2002 Sep;302(3):940-8.

PMID:
12183650
38.

Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

Ballard TM, Pauly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E, Kemp JA, Bluethmann H, Kew JN.

J Neurosci. 2002 Aug 1;22(15):6713-23.

39.

Neuregulin 1 and susceptibility to schizophrenia.

Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K.

Am J Hum Genet. 2002 Oct;71(4):877-92. Epub 2002 Jul 23.

40.

Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor.

Malherbe P, Knoflach F, Broger C, Ohresser S, Kratzeisen C, Adam G, Stadler H, Kemp JA, Mutel V.

Mol Pharmacol. 2001 Nov;60(5):944-54.

PMID:
11641422
41.

Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site.

Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, Kemp JA.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7. Epub 2001 Oct 23. Erratum in: Proc Natl Acad Sci U S A 2001 Dec 18;98(26):15393.

42.

Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.

Pinard E, Alanine A, Bourson A, Büttelmann B, Gill R, Heitz M, Jaeschke G, Mutel V, Trube G, Wyler R.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2173-6.

PMID:
11514163
43.

Pharmacological characterization of interactions of RO 25-6981 with the NR2B (epsilon2) subunit.

Lynch DR, Shim SS, Seifert KM, Kurapathi S, Mutel V, Gallagher MJ, Guttmann RP.

Eur J Pharmacol. 2001 Mar 30;416(3):185-95.

PMID:
11290368
44.

Pharmacological properties of native metabotropic glutamate receptors in freshly dissociated Golgi cells of the rat cerebellum.

Knoflach F, Woltering T, Adam G, Mutel V, Kemp JA.

Neuropharmacology. 2001;40(2):163-9.

PMID:
11114394
45.

Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections.

Mutel V, Ellis GJ, Adam G, Chaboz S, Nilly A, Messer J, Bleuel Z, Metzler V, Malherbe P, Schlaeger EJ, Roughley BS, Faull RL, Richards JG.

J Neurochem. 2000 Dec;75(6):2590-601.

46.
47.

Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors.

Schweitzer C, Kratzeisen C, Adam G, Lundstrom K, Malherbe P, Ohresser S, Stadler H, Wichmann J, Woltering T, Mutel V.

Neuropharmacology. 2000 Jul 24;39(10):1700-6.

PMID:
10884552
48.

Reducing conditions differentially affect the functional and structural properties of group-I and -II metabotropic glutamate receptors.

Copani A, Romano C, Di Giorgi Gerevini V, Nicosia A, Casabona G, Storto M, Mutel V, Nicoletti F.

Brain Res. 2000 Jun 9;867(1-2):165-72.

PMID:
10837810
49.

Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site.

Kew JN, Koester A, Moreau JL, Jenck F, Ouagazzal AM, Mutel V, Richards JG, Trube G, Fischer G, Montkowski A, Hundt W, Reinscheid RK, Pauly-Evers M, Kemp JA, Bluethmann H.

J Neurosci. 2000 Jun 1;20(11):4037-49.

50.

Regulation by neurotransmitter receptors of serotonergic or catecholaminergic neuronal cell differentiation.

Mouillet-Richard S, Mutel V, Loric S, Tournois C, Launay JM, Kellermann O.

J Biol Chem. 2000 Mar 31;275(13):9186-92.

Supplemental Content

Support Center